• Moderna posted an oncology presentation detailing intismeran autogene, an investigational mRNA-based individualized neoantigen therapy designed to each patient’s tumor and HLA type.
• Presentation highlighted a 5-year update from Phase 2 KEYNOTE-942 in resected melanoma using intismeran autogene with pembrolizumab.
• Disclosed manufacturing consistency in the study: 91% of combination-arm patients received products containing 34 targetable neoantigens.
• Reported limited commonality across patients’ targets: 99.1% of neoantigens were unique, reinforcing the therapy’s individualized design.
• Outlined a partnered development strategy with Merck, focused first on IO-sensitive tumors, with exploratory work in less IO-responsive cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.